Modafinil has an unusual reputation among so-called smart drugs. It was developed as a wakefulness-promoting medication, yet it is widely discussed as something more ambitious: a compound that might improve attention, memory, decision-making and mental performance even in healthy people who are already well rested.

There is enough research to say that this idea is not entirely fictional. Modafinil can influence cognition. But the effect depends heavily on what we mean by cognitive enhancement — and on the state of the person taking it.

In rested healthy adults, the average cognitive benefit seen across controlled trials is small. Under sleep deprivation or severe fatigue, the picture changes substantially: modafinil can preserve vigilance and aspects of performance that would otherwise deteriorate. The distinction matters because preventing a tired brain from performing badly is not the same thing as making a rested brain perform beyond its normal capacity.

Key Takeaways

• Modafinil does have measurable cognitive effects, but calling it a general-purpose “smart drug” overstates the evidence.
• In healthy, non-sleep-deprived adults, a 2019 meta-analysis of 19 placebo-controlled trials found a statistically significant but very small overall cognitive benefit: Hedges’ g = 0.10.
• Some individual trials report improvements in executive function, planning, working memory, response inhibition or difficult cognitive tasks, while other well-controlled studies find little or no meaningful improvement.
• The evidence is considerably stronger when normal performance has been compromised by sleep deprivation or fatigue. Controlled studies show improved vigilance and reduced sleepiness under these conditions.
• Modafinil affects the dopamine system in humans, including occupancy of dopamine transporters, but its pharmacology should not be reduced to “more dopamine = better cognition.” Mechanism does not predict the magnitude of cognitive enhancement.
• There is very little evidence that chronic modafinil use makes healthy people more intelligent, produces durable improvements in learning, or meaningfully improves long-term academic or professional performance.
• Modafinil is a prescription drug with clinically relevant risks and drug interactions. Cognitive enhancement is not an approved indication.

What Is Modafinil?

Modafinil is a wakefulness-promoting drug, sometimes described as a eugeroic. In the United States, Provigil is indicated for excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift-work disorder. Cognitive enhancement in healthy people is not an FDA-approved indication.

European regulation is more restrictive. Following a benefit-risk review, the European Medicines Agency recommended restricting modafinil-containing medicines to narcolepsy after raising concerns about serious skin, psychiatric and cardiovascular adverse reactions.

Its unusually long duration is relevant to both its therapeutic effects and its appeal as a productivity drug. The effective elimination half-life after repeated dosing is approximately 15 hours.

But wakefulness and cognition are not synonymous. Being less sleepy can obviously make someone perform better. The harder scientific question is whether modafinil improves cognitive processing independently of correcting fatigue.

That is where the evidence becomes much more nuanced.

Does Modafinil Improve Cognition in Healthy People?

Yes, but the average effect in rested healthy adults appears to be small, inconsistent and dependent on the cognitive task being measured. Modafinil is much better supported as a way of preserving cognitive performance during sleep loss than as a drug that broadly upgrades normal cognition.

The strongest quantitative summary comes from a 2019 systematic review and meta-analysis by Kredlow and colleagues. The researchers identified 19 placebo-controlled trials examining single-dose modafinil across attention, executive function, memory and processing speed, yielding 67 domain-specific effect sizes.

Across all cognitive domains, modafinil produced a statistically significant advantage over placebo.

But the magnitude was:

Hedges’ g = 0.10
95% CI: 0.05–0.15

That is a very small effect.

The researchers found no significant difference between cognitive domains and no clear evidence that 200 mg produced greater cognitive enhancement than 100 mg. Their conclusion was unusually direct: the available evidence suggested only limited potential for modafinil as a cognitive enhancer outside sleep-deprived populations.

A separate 2020 series of meta-analyses examining modafinil, methylphenidate and d-amphetamine in healthy non-sleep-deprived adults reached a broadly similar conclusion: modafinil showed only small overall enhancement, with limited domain-specific benefits rather than a dramatic generalized cognitive effect.

That distinction is central to understanding modafinil.

A statistically detectable cognitive effect exists.

A large, reliable transformation of normal cognitive ability does not.

Why Do Some Modafinil Studies Look Much More Impressive?

Because averages can hide task-specific effects.

Some individual studies have reported clear benefits.

In one influential randomized, placebo-controlled study, Turner and colleagues found improvements in digit span, visual pattern recognition memory, spatial planning and response inhibition in healthy volunteers given modafinil.

A later placebo-controlled study by Müller and colleagues also found benefits in healthy non-sleep-deprived volunteers, particularly when cognitive demands were high. Improvements appeared in spatial working memory, planning and decision-making at more difficult task levels, as well as delayed visual pattern recognition.

This helped generate an important hypothesis: modafinil may reveal its effects most clearly when cognitive processing becomes difficult enough to strain the system.

Under easy conditions, a healthy brain may already be operating close to ceiling. There is little room for a drug to improve a task on which most participants already perform well.

That hypothesis is plausible, but it does not make the negative studies disappear.

Several Trials Have Found Little or No Enhancement

Randall and colleagues examined healthy young volunteers who were not sleep-deprived and found no significant benefit from modafinil on several measures of long-term memory, executive function, visuospatial performance and constructional ability.

A larger randomized trial involving healthy university students similarly concluded that modafinil did not improve global cognitive performance in non-sleep-deprived students, despite some isolated effects on components of an attention task.

Even apparently positive effects can contain unexpected trade-offs.

In a randomized double-blind study of healthy adults, Mohamed and Lewis found that modafinil increased response latency on the Hayling Sentence Completion Test without improving response accuracy. In other words, participants sometimes spent longer processing the task without producing better answers.

This illustrates a broader problem in cognitive-enhancement research:

changing cognitive behavior is not necessarily the same as improving it.

What Cognitive Functions Might Modafinil Actually Improve?

The evidence is easier to interpret when cognition is separated into individual domains.

The most important pattern is therefore not simply:

modafinil improves cognition.

It is closer to:

modafinil can selectively improve certain cognitive processes under certain conditions, with effects becoming considerably more reliable as fatigue and cognitive demand increase.

Sleep Deprivation Changes the Story

This is where modafinil becomes much more convincing.

Sleep deprivation reliably impairs reaction time, vigilance, attention and executive functioning. A drug that promotes wakefulness therefore has considerably more room to produce a measurable improvement.

A 2023 randomized crossover trial illustrates the difference particularly well.

Thirty-two Royal Netherlands Air Force volunteers were tested after being awake for a median of approximately 17 hours. On different trial days they received 200 mg modafinil, 300 mg caffeine or placebo. Both active drugs reduced the effects of sleep loss on vigilance, but modafinil’s effects lasted longer: eight hours after administration, modafinil still significantly outperformed caffeine on psychomotor vigilance and subjective sleepiness.

This is not merely a historical military finding. Recent research continues to find the same general pattern.

A 2025 randomized crossover study followed 11 healthy military student pilots during 24 hours of extended wakefulness. Modafinil improved vigilance relative to placebo, but the magnitude of the effect differed markedly between individuals. The researchers found remarkably stable individual differences in the drug’s effect on reaction time.

The sample was very small, so it should not be used to estimate population-wide effects. But it highlights something that older studies often obscure:

there may not be one universal “modafinil response.”

Some people may derive much greater performance preservation than others.

Enhancement or Restoration?

This leads to a useful conceptual distinction.

Imagine cognitive performance on a simplified scale:

Sleep deprived → Normal rested performance → Above-normal performance

Modafinil appears particularly good at moving people from the left toward the middle.

The evidence that it reliably moves healthy, well-rested people far from the middle toward the right is much weaker.

That is why describing modafinil simply as a cognitive enhancer can be misleading.

A more scientifically accurate description may be:

a wakefulness-promoting drug that can preserve or partially restore cognitive performance under conditions of fatigue, with smaller and less consistent enhancement effects in already-rested healthy adults.

This interpretation also explains why the drug’s reputation may exceed its effect size in laboratory meta-analyses.

Why Can Modafinil Feel More Powerful Than Cognitive Tests Suggest?

Someone using modafinil to work for several hours may report a dramatic increase in productivity even if standardized cognitive tests show only a small change.

Those observations are not necessarily contradictory.

Productivity depends on more than memory or IQ.

It also depends on:

• wakefulness,
• resistance to fatigue,
• willingness to continue working,
• sustained task engagement,
• distractibility,
• perceived effort.

Some experimental work suggests modafinil may influence task engagement or the experience of performing cognitively demanding work, while cognitive-training research has found faster learning during early training sessions when modafinil was paired with repeated practice.

That creates an important distinction:

feeling able to work longer and stay engaged is not the same biological claim as possessing more cognitive capacity.

A person who remains focused on a document for six hours instead of becoming sleepy after three may legitimately accomplish more work.

That does not mean their memory, reasoning ability or intelligence has increased by an equivalent amount.

How Might Modafinil Affect the Brain?

Modafinil has often been portrayed as a fundamentally different kind of stimulant from amphetamine. Its pharmacology is indeed different, but one popular claim — that it operates without meaningful involvement of dopamine — is not supported by human evidence.

A PET imaging experiment led by Nora Volkow studied 10 healthy men given modafinil and found substantial occupancy of dopamine transporters in the striatum together with increases in extracellular dopamine, including in the nucleus accumbens.

The official US prescribing information likewise notes that modafinil binds to the dopamine transporter and inhibits dopamine reuptake, although the full mechanism responsible for its wakefulness-promoting effects remains unresolved.

Recent neuroimaging work continues to suggest that modafinil alters larger-scale brain-network activity as well. A 2025 study reported changes in functional connectivity between specific thalamic nuclei and cortical regions after modafinil administration. Such findings may eventually help explain how the drug affects attention and arousal, but they do not demonstrate cognitive enhancement by themselves.

This distinction is essential:

a measurable effect on dopamine transporters or brain connectivity establishes pharmacological activity — not a meaningful improvement in human cognition.

Why Are the Results So Inconsistent?

Several explanations are likely operating simultaneously.

1. Ceiling effects

Healthy, rested people already perform well on many standard neuropsychological tests. Modafinil may have little opportunity to improve an easy task.

The same person tested after prolonged wakefulness provides substantially more room for improvement.

2. Task difficulty

Positive effects have sometimes emerged only at higher levels of cognitive demand. This may explain why sophisticated executive tasks can produce different results from simple reaction-time or memory tests.

3. Different cognitive domains respond differently

“Cognition” is not a single variable.

Working memory, episodic memory, vigilance, inhibitory control, processing speed and creativity depend on overlapping but distinct neural systems.

A compound can improve one while doing nothing — or potentially something undesirable — to another.

4. Individual differences

The 2025 military study provides particularly striking evidence that response to modafinil can differ consistently between individuals, although the small sample means the finding requires replication in larger populations.

5. Small studies

Much of the healthy-volunteer literature consists of relatively small acute experiments. Small samples increase uncertainty around true effect sizes and make apparent positive or negative findings less stable.

6. Laboratory endpoints are not real life

Improving performance on a computerized planning task does not automatically mean someone will become a better programmer, physician, student or entrepreneur.

The translation from experimental cognition to meaningful long-term achievement has barely been established.

The Missing Evidence: Long-Term Cognitive Enhancement

One of the largest weaknesses in the “smart drug” argument is that most controlled evidence concerns acute administration.

The 2019 meta-analysis specifically examined single-dose effects. The 2020 meta-analysis likewise focused on acute pharmacological enhancement in healthy adults.

That means several practically important questions remain unanswered.

We do not have convincing evidence that chronic modafinil use in healthy people:

• produces lasting improvements in memory,
• raises general intelligence,
• improves long-term academic outcomes,
• improves career performance,
• accelerates durable skill acquisition,
• produces a favorable long-term benefit-risk ratio as a cognitive enhancer.

These are not small gaps.

They are precisely the outcomes many people have in mind when they hear the term nootropic.

Could Modafinil Still Be Considered a Nootropic?

It depends on the definition.

If nootropic means:

any compound capable of measurably improving at least some aspects of cognitive performance,

then modafinil qualifies reasonably well.

If it means:

a drug that reliably makes a healthy, rested person broadly smarter,

the evidence does not support that description.

And if cognitive enhancement includes maintaining performance when the brain is compromised by fatigue, the case becomes substantially stronger.

This gives modafinil an unusual position among proposed cognitive enhancers.

It is neither a placebo dressed up as a smart drug nor the pharmaceutical equivalent of adding processing power to the brain.

Its most convincing effect lies somewhere in between:

protecting performance when normal cognitive capacity begins to deteriorate.

What About Safety?

The relatively modest average cognitive gain in rested healthy people matters because modafinil is not physiologically neutral.

The US prescribing information lists headache, nausea, nervousness, anxiety, insomnia and dizziness among adverse reactions and carries warnings concerning serious rash, including Stevens-Johnson syndrome, hypersensitivity reactions, psychiatric symptoms and cardiovascular events.

The EMA’s European review similarly highlighted serious skin reactions, psychiatric adverse reactions and cardiovascular concerns when reassessing modafinil’s benefit-risk profile.

There are also clinically important pharmacokinetic interactions. Modafinil can induce CYP3A4/5 activity and reduce exposure to some drugs. Of particular practical importance, it can reduce the effectiveness of steroidal hormonal contraceptives; the US prescribing information recommends alternative or additional contraception during treatment and for one month after discontinuation. It can also affect drugs including cyclosporine and several CYP2C19 substrates.

Modafinil’s action on dopamine transporters is also relevant to abuse liability. Human PET data demonstrate increased extracellular dopamine in reward-related regions, and the US product information classifies Provigil as a Schedule IV controlled substance.

This does not mean modafinil carries the same abuse profile as classical amphetamine stimulants.

It does mean that describing it as a benign productivity supplement would be scientifically inappropriate.

Evidence Strength Summary



So, Is Modafinil a Cognitive Enhancer?

The scientifically defensible answer is:

Yes — but only under a narrower definition of cognitive enhancement than the term “smart drug” usually implies.

Modafinil is capable of altering cognitive performance in healthy humans. Across controlled studies, selective benefits have appeared in executive function, working memory, planning, inhibitory control and other demanding tasks. That prevents us from dismissing its nootropic effects entirely.

But when the literature is pooled, the effect in healthy, non-sleep-deprived adults becomes much less dramatic. The best-known meta-analysis found an average effect of only g = 0.10, which is very small.

The strongest case emerges when sleep loss is introduced. Under fatigue, modafinil can clearly protect vigilance and performance.

That suggests a hierarchy:

Sleep-deprived brain: substantial potential benefit
Fatigued/high-demand brain: plausible and sometimes meaningful benefit
Healthy rested brain: small and inconsistent benefit
Long-term enhancement beyond normal ability: unproven

So modafinil may reasonably be called a cognitive enhancer.

But “cognitive performance stabilizer under adverse conditions” may describe the evidence more accurately than “smart drug.”

Bottom Line

Modafinil occupies a scientifically interesting middle ground.

It is one of the relatively few prescription drugs for which controlled studies genuinely do provide evidence of cognitive effects in healthy people. The effect is not simply imaginary, and some experiments show convincing improvements in demanding executive tasks.

At the same time, the mythology surrounding modafinil has outgrown the data.

In rested healthy adults, the average cognitive benefit is small. Improvements are selective rather than global, vary substantially across studies and individuals, and have mostly been measured after acute administration in laboratory settings.

Where modafinil becomes much more impressive is when the brain is fighting sleep.

That may be the most important distinction in the entire literature:

Modafinil appears considerably better at preventing cognitive decline caused by fatigue than at pushing normal cognition significantly beyond baseline.

Whether that is sufficient to call it a nootropic depends on the definition.

Whether it makes healthy people broadly “smarter” is a different question.

At present, the evidence says no.

Frequently Asked Questions

Does modafinil improve focus?

It can. The strongest effects on sustained vigilance appear during fatigue or sleep deprivation. In rested healthy adults, attention-related improvements are much less consistent, and pooled evidence indicates only a small overall cognitive effect.

Does modafinil improve memory?

Some controlled trials report improvements in particular memory tasks, including pattern recognition and aspects of working memory, while others find no meaningful benefit. Meta-analytic evidence does not support a large generalized improvement in memory.

Is modafinil more effective when you are sleep deprived?

Yes. This is one of the clearest conclusions from the literature. Controlled studies show that modafinil reduces deterioration in vigilance and subjective sleepiness during extended wakefulness. Its effectiveness as a fatigue countermeasure is substantially better supported than its ability to enhance an already well-rested brain.

Does modafinil increase dopamine?

Yes, although this is only part of its pharmacology. PET imaging in healthy humans has shown dopamine-transporter occupancy and increased extracellular dopamine in the striatum, including the nucleus accumbens. The precise network-level mechanisms underlying wakefulness and cognitive effects remain incompletely understood.

Is modafinil safer than traditional stimulants?

Its pharmacological and subjective profile differs from classical amphetamine stimulants, but “safer” should not be interpreted as harmless. Modafinil can cause insomnia, anxiety and headache, has important drug interactions, and rare but serious dermatological, hypersensitivity, psychiatric and cardiovascular adverse reactions have been reported.

Can modafinil make you smarter?

There is no convincing evidence that modafinil increases general intelligence. It may improve selected aspects of cognitive performance, particularly under demanding or sleep-deprived conditions, but this is very different from raising overall intellectual capacity.

Is modafinil approved as a cognitive enhancer?

No. Cognitive enhancement in healthy people is not an approved indication. US prescribing information covers excessive sleepiness associated with specific sleep disorders, while European regulators restricted indications following a benefit-risk review.

References

1. Kredlow MA, Keshishian A, Oppenheimer S, Otto MW. (2019). The Efficacy of Modafinil as a Cognitive Enhancer: A Systematic Review and Meta-Analysis. Journal of Clinical Psychopharmacology. Meta-analysis of 19 placebo-controlled trials.
2. Roberts CA et al. (2020). How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and d-amphetamine. European Neuropsychopharmacology.
3. Battleday RM, Brem AK. (2015). Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. European Neuropsychopharmacology.
4. Turner DC et al. (2003). Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology. Randomized placebo-controlled study.
5. Randall DC et al. (2005). Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived? Journal of Clinical Psychopharmacology.
6. Müller U et al. (2013). Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology.
7. Gilleen J et al. (2014). Modafinil combined with cognitive training is associated with improved learning in healthy volunteers — a randomised controlled trial. European Neuropsychopharmacology.
8. Mohamed AD, Lewis CR. (2014). Modafinil increases the latency of response in the Hayling Sentence Completion Test in healthy volunteers: a randomised controlled trial. PLOS ONE.
9. Fernández A et al. (2015). Effects of modafinil on attention performance, short-term memory and executive function in university students: a randomized trial.
10. Wingelaar-Jagt YQ et al. (2023). Effects of modafinil and caffeine on night-time vigilance of air force crewmembers: A randomized controlled trial. Journal of Psychopharmacology.
11. Van Cutsem J et al. (2025). Stable interindividual differences in modafinil’s effect on vigilance during sleep deprivation. Frontiers in Pharmacology.
12. Volkow ND et al. (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. PET study in healthy volunteers.
13. US DailyMed — Provigil prescribing information. Official prescribing information covering indications, pharmacology, safety and interactions.
14. European Medicines Agency. Modafinil Article 31 referral and benefit-risk review.

Editorial disclaimer: This article is for educational purposes only and does not constitute medical advice. Modafinil is a prescription medication; potential benefits, contraindications, interactions and risks should be discussed with an appropriately qualified healthcare professional.